Milbank LLP has advised the shareholder of FormMed Healthcare AG ("FormMed"), a leading developer and supplier of micronutrition for therapeutic use, on the majority sale to Avedon Capital Partners (“Avedon”), a mid-cap focused private equity investor.
The founder, Dr. Martin Lemperle, will retain a significant stake in FormMed and will actively shape its further development.
Founded in 1996, FormMed provides the largest range of supplements in the micronutrition space tailored to the specific needs of medical professionals and their patients. The modular product range includes indication-specific- and active ingredient micronutrients and enables medical professionals to recommend entire supplement treatment concepts, according to their patients need, at an affordable price. FormMed fulfills the highest quality and purity standards in the market, “Made in Germany."
Together with Avedon, FormMed seeks to further accelerate growth in Germany and internationalize to selected European core markets. This includes the focused expansion of the product portfolio and the further development of the organization, as well as cooperation with selected distribution partners.
The Milbank team that advised the seller comprehensively on the corporate and tax aspects of the transaction was led by partner Michael Bernhardt (Corporate/M&A, Frankfurt) and included partner Matthias Schell (Tax, Munich) as well as special counsel Sebastian Dexheimer and associates Sarah-Maria Resch, Johannes Wohlmuth and Leonard Mittmann (all Corporate/M&A, Frankfurt).
